National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab (Opdivo®) as monotherapy for unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (2L). HTA ID: 20057

Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 15/12/2020
Rapid review completed 13/01/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that nivolumab not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.